Drug Trial Radar · NCT01605136
Phase III Confirmatory Study in Erythropoietic Protoporphyria
Last checked: Nov 20, 2026Latest source record: Sep 19, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
93
Actual
Start
May 2012
Primary completion
Jul 2013
Study completion Jul 2013
Sponsor
- Lead sponsor
- Clinuvel Pharmaceuticals LimitedIndustry
- Sponsor type
- Industry
- First posted
- May 24, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized placebo-controlled study to be conducted in two parallel study arms for a six month period (three doses). Between 75 and 100 eligible patients will be enrolled. Patients will receive afamelanotide (16 mg implants) or placebo according to the following dosing regimen: * Group A will be administered afamelanotide implants on Days 0, 60 and 120 * Group B will be administered placebo implants on Days 0, 60 and 120 The number and severity of phototoxic reactions, the type and duration of sun exposure, treatment-emergent adverse events and the use of concomitant medication will be recorded by patients in study diaries between Days 0 and 180. Quality of life will be measured using the DLQI and EPP-QoL at Days 0, 60, 120 and 180. Participants will visit the clinic on Days 60, 120 and 180 for assessments of adverse events. A subset of patients will be photoprovoked on the lower back and dorsal surface of the hand and the minimal symptom dose (MSD) will be determined on Days 0, 30, 60, 90 and 120.
Conditions
- Erythropoietic Protoporphyria
Interventions
AfamelanotideDrug
One 16mg subcutaneous implant every 2 months for 6 months.
PlaceboDrug
One placebo subcutaneous implant every 2 months for 6 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Duration of Direct Sunlight Exposure Between 10:00 and 18:00 Hours on Days When no Pain Was Experienced (Pain Score of 0).Time frame: Daily for 6 months
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama
Birmingham, Alabama
University of California, San Francisco
San Francisco, California
Henry Ford Medical Center
Detroit, Michigan
Mt. Sinai
New York, New York
Carolina's Medical Center Cannon Research
Charlotte, North Carolina
University of Texas
Galveston, Texas
University of Utah
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.